Recombinant Anti-CD22 × Anti-CD79B Bispecific Antibody (Tandem Diabody)

Customer Review

There are currently no Customer reviews or questions for TAND-LC001. Click the button above to contact us or submit your feedback about this product.

Q&As

1. Is this antibody suitable for Antibody-Drug Conjugate (ADC) research?

   A: Yes, this bispecific antibody targeting CD22 and CD79B is highly suitable for ADC research. Both targets are known to internalize upon antibody binding. By targeting both simultaneously, you can potentially enhance the internalization rate and lysosomal delivery of cytotoxic payloads in B cell malignancies.

2. What specific cell types does this antibody target?

   A: This antibody is designed to target B cell lineages, specifically those expressing CD22 and CD79B. These antigens are commonly found on B cell lymphomas and leukemias, making this product a valuable tool for researching targeted therapies for B cell-derived hematological cancers.

View the frequently asked questions answered by Creative Biolabs Support.

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Datasheet

MSDS

COA

Certificate of Analysis Lookup

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.